|Title:||Methods for treating allergic disorders using optically pure (-) cetirizine|
|Abstract:||Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.|
|Inventor(s):||Gray; Nancy M. (Marlboro, MA)|
|Assignee:||Sepracor, Inc. (Marlborough, MA)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form; Composition;|
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Netherlands||300085||May 01, 2002|
|European Patent Office||0663828||Jul 26, 1995||2002C/005||Belgium||<disabled>|
|European Patent Office||0663828||Sep 09, 1998||C300085||Netherlands||<disabled>|
|European Patent Office||0663828||Jul 26, 1995||10/2002||Austria||<disabled>|
|European Patent Office||0663828||Jul 26, 1995||C300085||Netherlands||<disabled>|
|This preview shows a limited data set|
Subscribe for full access
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.